ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
0.9100
-0.0328 (-3.48%)
At close: Mar 28, 2025, 4:00 PM
0.9201
+0.0101 (1.11%)
Pre-market: Mar 31, 2025, 7:06 AM EDT
Company Description
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States.
The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.
ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 204 |
| CEO | Bruce Culleton |
Contact Details
Address: 2000 Frontis Plaza Blvd., Suite 250 Winston-Salem, North Carolina 27103 United States | |
| Phone | 336 999 7028 |
| Website | prokidney.com |
Stock Details
| Ticker Symbol | PROK |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850270 |
| ISIN Number | KYG7S53R1049 |
| Employer ID | 98-1586514 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bruce Culleton M.D. | Chief Executive Officer and Director |
| Dr. Ulrich Ernst Ph.D. | Executive Vice President of Science and Technology |
| Todd C. Girolamo Esq., J.D., M.B.A. | Chief Legal Officer and Secretary |
| Anu Biswas | Senior Vice President of Manufacturing and Operations |
| Richard Williams | Chief Information Officer |
| Carla Poulson | Chief People Officer |
| Dr. Joseph M. Stavas M.D., M.P.H. | SVice President of Clinical Affairs |
| Dr. Darin J. Weber Ph.D. | Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access |
| Nikhil L. Pereira-Kamath | Chief Business Officer |
| Dr. Emily Butler Ph.D. | Senior Vice President of Biometric |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 17, 2025 | 8-K | Current Report |
| Feb 6, 2025 | SCHEDULE 13D/A | Filing |
| Jan 21, 2025 | 8-K | Current Report |
| Nov 22, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |